CARsgen Therapeutics repurchases shares, boosting treasury holdings

On November 6, 2025, CARsgen Therapeutics Holdings Limited announced the repurchase of 1,734,000 ordinary shares on the Exchange. These shares were bought at a volume-weighted average price of HK$15.17, with the highest repurchase price at HK$15.8 and the lowest at HK$14.35. The total aggregate price paid for these repurchases amounted to HK$26,307,848.5. This activity represents a 0.3% change relative to the company's existing issued shares before the event.

As a result of these repurchases, the number of shares held as treasury shares increased by 1,734,000 to a new closing balance of 1,734,000 on November 6, 2025. The total number of issued shares (excluding treasury shares) consequently decreased from 577,942,405 to 576,208,405. The repurchase mandate, authorizing up to 57,543,590 shares, was granted on May 22, 2025, and as of November 6, 2025, a total of 2,189,000 shares have been repurchased under this mandate, representing 0.3804% of the issued shares at the mandate's grant date.

Additionally, the company reported two previous share repurchase events for cancellation that have not yet been cancelled. On October 21, 2025, 250,000 shares were repurchased at HK$17.08, and on October 23, 2025, 205,000 shares were repurchased at HK$16.58. A moratorium period for issuing new shares or transferring treasury shares after these repurchases is in effect until December 6, 2025.